Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform.
The stock rose 7.77% in pre-market trading on June 3, 2025, reflecting investor optimism about the company’s strategic expansion into Europe. HIMS shares closed at $56.77 on Monday, reflecting a year-to-date increase of approximately 134.78% and a 39.07% gain over the past month.
The company’s recent announcement to acquire ZAVA, a leading European digital health platform, marks a significant step in its international growth strategy. This acquisition will enable Hims & Hers to expand its services into Germany, France, Ireland, and strengthen its presence in the United Kingdom.
Hims & Hers revenue
Financially, Hims & Hers reported a 111% year-over-year revenue growth in Q1 2025, reaching $586 million, with a net income of $49.5 million. The company’s subscriber base also expanded by 38%, totaling nearly 2.4 million users.
Despite regulatory challenges, including the FDA’s decision to end the shortage status of semaglutide, impacting the company’s compounded weight-loss drug offerings, Hims & Hers has demonstrated resilience. The company is diversifying its portfolio, focusing on personalized healthcare solutions, and exploring new treatment categories such as low testosterone and menopause.
Overall, the acquisition of ZAVA positions Hims & Hers to capitalize on the growing demand for digital healthcare solutions in Europe, potentially driving further growth and shareholder value in the coming years.
Featured image via Shutterstock
